Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danggui Sini granule for prevention of oxaliplatin-induced peripheral neurotoxicity in colorectal cancer
ChiCTR2300079315Phase 3Not yet recruiting
- Sponsor
- Jiangsu Province Hospital on Integration of Chinese and Western Medicine
- Start
- Dec 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in peripheral neuropathy comparing Oxaliplatin chemotherapy + Danggui Sini granule with Oxaliplatin chemotherapy + placebo (2 arms). Primary endpoint: Incidence of peripheral neurotoxicity. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
danggui sini
03
Conditions
peripheral neuropathy
Beyond the preview
Go deeper on ChiCTR2300079315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079315.